2013


To access this material please log in or register

Register Authorize
2013/№2

Comparative efficacy and safety of chronic torasemide and furosemide therapy in patients with compensated heart failure. Effect on markers of myocardial fibrosis

Ageev F. T., Zhubrina E. S., Gilyarevsky S. R., Mareev V. Yu., Khoseva E. N., Golshmid M. V., Deev A. D., Kotkina T. I., Lukina Yu. V., Malishevsky M. V., Masenko V. P., Rogozhkina Yu. A., Seredenina E. M., Sinitsina I. I., Suslikov A. V., Titov V. N.

Keywords: NT-proBNP, aldosterone, fibrosis markers, loop diuretic, CHF

DOI: 10.18087 / rhfj.2013.2.1801

Background. The use of loop diuretics plays an important role in therapy for symptomatic CHF. Aim. Comparative evaluation of clinical efficacy of torasemide (Trigrim®, Polpharma, Poland) and furosemide (N. A. Semashko Moskhimfarmpreparaty) in patients with CHF and effect of these therapies on markers of myocardial fibrosis. Materials and methods. 108 patients with compensated II–III NYHA FC CHF receiving a standard therapy for HF were randomized to groups receiving torasemide (n=55; mean dose, 9.8±5.9 mg) or furosemide (n=53; mean dose, 28.7±14.7 mg). Clinical and hemodynamic status, quality of life, LV function, and serum levels of electrolytes, aldosterone, procollagen type I C-terminal propeptide (PICP), the marker of type I collagen synthesis, and С-terminal telopeptide of collagen type I (CITP), the marker collagen type I degradation. Results. Study results demonstrated safety and efficacy of the loop diuretics, torasemide and furosemide, for reducing the average FC and severity of clinical condition and increasing the quality of life in patients with moderately compensated CHF (р<0.05 for all comparisons). However only the torasemide therapy was associated with significantly increased 6min walk distance and LV contractility, improved Doppler parameters of LV filling pressure (Е / e′) and considerably decreased NT-proBNP and aldosterone (р<0.05 for all comparisons). At the same time, the furosemide therapy was associated with significant increases in the type I collagen synthesis marker, PICP and the PICP / CITP ratio (р<0.05). Conclusion. This study showed that both torasemide and furosemide are safe and effective for decreasing the FC and increasing the quality of life in patients with compensated CHF. However the clinical hemodynamic effect of torasemide is superior to that of furosemide, probably due to additional antialdosterone mechanisms of torasemide, which may influence the heart function including synthesis of collagen type I.
  1. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33 (14):1787–1847.
  2. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  3. Cosin J, Diez J. Torasemide in chronic heart failure: Results of the TORIC study. Eur J Heart Fail. 2002;4 (4):507–513.
  4. Преображенский Д. В., Некрасова Н. И., Талызина И. В., Патарая С. А. Торасемид – петлевой диуретик нового поколения: особенности фармакологии и клиническая эффективность при сердечной недостаточности. Журнал Сердечная недостаточность. 2010;11 (5):294–300.
  5. Friedel H, Buckley MM. Torasemide. A review of its pharmacology and therapeutic potential. Drugs. 1991;41 (1):81–103.
  6. Fortuno A, Muniz P, Ravassa S et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999;34 (1):138–143.
  7. Uchida T, Yamanaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol. 1991;205 (2):145–150.
  8. Uchida T, Yananaga K, Kido H et al. Diuretic and vasodilating actions of torasemide. Cardiology. 1994;84 (Suppl 2):14–17.
  9. Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torasemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63 (3):PL45–50.
  10. Tsutamoto T, Sakai H, Wada A et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 2004;44 (11):2252–2253.
  11. Brater DC. Diuretic therapy. N Engl J Med. 1998;339 (6):387–395.
  12. Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med. 1994;154 (17):1905–1914.
  13. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Е. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. – М.: «Гэотар-Медиа», 2006. – 432 с.
  14. Brater DC. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf. 1996;14 (2):104–120.
  15. Kido H, Ohtaki Y. Torasemide (LUPRAC): a review of its pharmacolo­gical and clinical profile. Nihon Yakurigaku Zasshi. 2001;118 (2):97–105.
  16. Nagueh SF, Appleton CP, Gillebert TC et al. Recommendations for the evaluation of left ventricular diastolic function by echocardio­graphy. J Am Soc Echocardiogr. 2009;22 (2):107–133.
  17. Мареев В. Ю., Выгодин В. А., Беленков Ю. Н. ДиУретическая терапия Эффективными дозами перораЛьных диуретиков торасемида (диувера) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ–ХСН). Журнал Сердечная Недостаточность. 2011;12 (3):3–10.
  18. Noe LL, Vreeland MG, Pezzella SM, Trotter JP. A pharmacoeconomic assessment of torasemide and furosemide in the treatment of patients with congestive heart failure. Clin Ther. 1999;21 (5):854–866.
  19. Opie L, Kaplan N. Diuretics. In: Opie L, Gersh B. (eds): Drugs for the heart (6th ed). Elsevier Saunders 2005; pp. 80–103.
  20. Азизова А., Овчинников А., Агеев Ф. Сравнительное влияние торасемида и фуросемида на клинический статус и диастолическую функцию левого желудочка у больных с компенсированной сердечной недостаточностью и высоким давлением наполнения левого желудочка. Журнал Сердечная Недостаточность 2011;12 (6):326–332.
  21. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV – efficacy and quality of life. Eur J Heart Fail. 2003;5 (6):793–801.
  22. Stauch M, Stiehl L. Controlled, double-blind clinical trial on the efficacy ans tolerance of torasemide in comparison with furosemide in  patients with congestive heart failure – a multicenter study. In: Progress in Pharmacology and Clinical Pharmacology. Ed. By F. M. Eichelbaum et al. vol. 8. № 1. Stuttgart New York. 1990. pp. 121–126.
  23. Bettencourt P. NT-proBNP and BNP: biomarkers for heart failure management. Eur J Heart Fail. 2004;6 (3):359–363.
  24. Lee SC, Stevens TL, Sandberg SM et al. The potential of brain natriuretic peptide a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail. 2002;8 (3):149–154.
  25. Koglin J, Pehlivanli S, Schwaiblmair M et al. Role of brain natriuretic peptide in risk stratification of patient with congestive heart failure. J Am Coll Cardiol. 2001;38 (7):1934–1941.
  26. Meta-Analysis Research Group in Echocardiography (MeRGE) AMI Collaborators. Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: an individual patient meta-analysis: Meta-Analysis Research Group in Echocardiography acute myocardial infarction. Circulation. 2008;117 (20):2591–2598.
  27. Lopez B, Querejrta R, Gonzalez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43 (11):2028–2035.
  28. Yamato M, Sasaki T, Honda K. et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67 (5):384–390.
Ageev F. T., Zhubrina E. S., Gilyarevsky S. R. et al. Comparative efficacy and safety of chronic torasemide and furosemide therapy in patients with compensated heart failure. Effect on markers of myocardial fibrosis. Russian Heart Failure Journal. 2013;14 (2):55-62

To access this material please log in or register

Register Authorize
Ru En